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S42 Podium Presentations
resolved by week 4. No clinically significant abnormalities on
neurological exam, ECG, cognitive testing (HVLT-R) and postural
vital signs were noted.
Conclusions: A single infusion of RN624 reduced pain in sub-
jects with OA of the knee. The peak effect on pain reduction
was observed at approximately 4 weeks post infusion and sus-
tained for 8 weeks thereafter. The reduction in pain was more
pronounced in walking pain. RN624 improved the subject’s func-
tional status including reduced pain while walking, improved
functional activities, and less stiffness (WOMAC subscales). A
trend of dose response in pain reduction was observed among
the lower dose cohorts 3, 10, 30, 100 μg/kg RN624 and the
maximum effect was observed in the 100 μg/kg RN624 group.
The abnormal pain-related adverse events observed appear to
be dose related. The onset and resolution occurred during the
first 4 weeks before the peak effect. The timing of the adverse
events coincided with the reduced efficacy seen transiently in
higher dose groups.
RN624, with well-defined pain relief and tolerability profiles, has
the potential to be useful in the management of chronic pain due
to OA.
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Purpose: The 110kd fibronectin-fragment (FN-f) has been found
to stimulate chondrocyte MMP-13 expression through the activa-
tion of an α5β1 integrin cell-signaling pathway. We have recently
shown that reactive oxygen species (ROS) are required sec-
ondary messengers in the activation of key components of this
pathway including PYK-2, MAP kinases, c-Jun, and NFkB. Ox-
idation of specific cysteine residues, resulting in the formation
of protein sulfenic acids, is a key step in several redox-sensitive
signaling pathways but has not been investigated in integrin path-
ways or in chondrocyte signaling. The objective of the present
study was to utilize a proteomics approach to determine key
redox proteins regulated by sulfenic acid formation in α5β1 sig-
naling that results in chondrocyte MMP-13 expression.
Methods: Human articular chondrocytes, isolated from nor-
mal ankle cartilage, were stimulated in serum-free media with
25μg/ml of the 110kD FN-f in the presence and absence of dime-
done, a reagent which reacts specifically with protein sulfenic
acids. The requirement for sulfenic acid formation in FN-f me-
diated integrin signaling was determined by pre-treating cells
with dimedone (0, 1, 5, 10, 20mM) for 30 mins followed by FN-f
stimulation. Activation of PYK2, MAP kinases, Akt, c-Jun and
NF-κB was measured by immunoblotting cell lysates, prepared
5-45 mins after FN-f stimulation, with phosphorylation-specific
antibodies while MMP-13 production was measured in the con-
ditioned media from cultures treated overnight. Cell survival was
analyzed by staining with calcein and ethidium bromide. Detec-
tion of sulfenic acid-containing proteins formed in response to
FN-f stimulation was performed by adding 5mM of a biotinylated
dimedone analogue (DCP-biotin) to the cell lysis buffer after
FN-f stimulation (rather than pre-treating with dimedone). Un-
stimulated controls were also treated with DCP-biotin in a similar
fashion. Labeled proteins were then pulled down with streptavidin
beads and analyzed on 1-D and 2-D gels.
Results: Pre-treatment with dimedone significantly inhibited FN-
f-stimulated MMP-13 production in a dose dependent manner
with maximal inhibition at 20mM with no reduction in cell sur-
vival at this dose. The inhibition of MMP-13 production was
associated with inhibition of phosphorylation of PYK2 and the
MAP kinases ERK, JNK, and p38 as well as c-Jun and the p65
subunit of NFκB. Of these, the JNK-2 isoform appeared to be
most sensitive with inhibition noted at 5mM dimedone while the
others required 10-20mM. Unlike the others, phosphorylation of
Akt, which is required for anabolic rather than catabolic signal-
ing, was increased with 20mM dimedone pre-treatment. When
DCP-biotin was added after FN-f stimulation, at least 5 proteins
containing sulfenic acid were noted that were uniquely labeled
in FN-f stimulated samples compared to controls. One of these
was identified as JNK-2. Sulfenic acid formation in JNK-2 was
confirmed in chondrocytes transfected with a Flag-tagged JNK-2
expression construct.
Conclusions: These results are the first to show that generation
of protein sulfenic acids is required for the FN-f stimulated inte-
grin signaling which mediates MMP-13 production. JNK-2 was
identified as a key redox-sensitive signaling intermediate but oth-
ers upstream of PYK2 are also likely involved. The specific Cys
residue modified to Cys sulfenic acid in JNK-2 is currently being
identified. Defining the redox sensitive secondary messengers
that regulate MMP-13 expression should aid in the develop-
ment of novel therapeutic targets capable of reducing cartilage
destruction in arthritis.
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Purpose: Degradation of articular cartilage characterised by pro-
teolysis of aggrecan and the type II collagen network is a central
feature of osteoarthritis (OA). Significant collagenolysis by matrix
metalloproteinases (MMPs) may signify the point of irreversible
cartilage damage. Numerous catabolic agents upregulate chon-
drocyte synthesis of MMPs, but the mechanism whereby these
enzymes are activated is unclear. Increased levels of Activated
Protein C (APC), an anticoagulant serine protease, are found in
OA. APC is generated through the action of thrombin bound to
thrombomodulin (TM) cleaving protein C (PC) bound to a its cell
surface receptor (EPCR). APC is known to activate MMP-2 but its
potential role in cartilage degradation has not been investigated.
Methods: Ovine articular cartilage was cultured ± 10ng/ml IL-1,
100ng/ml TNF-alpha or 10-6M retinoic acid (RA) ± 2-20 μg/ml
APC ± a broad spectrum MMP inhibitor (marimastat, 300nM) for
4 days. In some experiments cartilage was cultured with APC for
24-96 hours, washed and then incubated with IL-1 or RA. The
release of sulfated glycosaminoglycan (GAG) and hydroxyproline
(HyPro) was compared using ANOVA and Student-Newman-
Keuls post-hoc analysis. MMP-2 and -9 activity in media was
examined by gelatin zymography, and MMP-13 activity measured
with a fluorogenic substrate. In replicate cultures, RNA was
extracted from cartilage and expression of ADAMTS-1, -4 &-5;
MMP-1, -2, -3, -9, -13 &-14; TIMPs 1-4; and PC, EPCR and
TM were evaluated using RT-PCR. PC was immunolocalised
in osteochondral sections of developing human joints and in
cartilage from normal and OA human cartilage.
Results: IL-1, TNF and RA significantly increased cartilage
GAG release (40-60% of total) but did not induce collagen
breakdown over 4 days of culture. APC alone (2-20μg/ml)
had no effect on GAG or collagen release, however, it sig-
nificantly augmented GAG loss from IL-1 and TNF (>80% of
total) but not RA stimulated cultures. In IL-1 and TNF but not
RA stimulated cultures, APC caused substantial collagen (4-
15% of total) loss over 4 days. MMP inhibition abrogated the
APC-augmented GAG and collagen release. Pre-culture with
APC prior to washing and subsequent cytokine stimulation, in-
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duced similar increased GAG and collagen release as when
co-incubated with cytokines. APC markedly increased MMP-2
activation (>80%) in IL-1 and TNF, but not RA treated cultures,
despite elevated pro-MMP-2 levels in the latter. APC increased
MMP-13 activity in IL-1 and TNF but not RA media, but could
not directly activate recombinant pro-MMP-13. APC did not sig-
nificantly modulate ADAMTS, MMP or TIMP expression when
administered alone or in combination with IL-1, TNF or RA.
Chondrocytes expressed mRNA for PC, EPCR and TM and
levels were not affected by APC or RA treatment. However,
IL-1 and TNF increased EPCR (1.7 & 3.8 fold, respectively)
and TM (5 and 18 fold, respectively) expression. PC was im-
munolocalised to chondrocytes in the presumptive joint space
prior to cavitation, the hypertrophic zone of the growth plate,
and throughout the depth of the cartilage in OA but not normal
joints.
Conclusions: Our results demonstrate that APC can act as an
efficient activator of MMPs in cartilage, inducing significant ag-
grecan and collagen degradation. Chondrocytes have previously
been shown to synthesise thrombin, and we have now demon-
strated that they express PC EPCR and TM necessary for its
efficient activation. PC was immunolocalised to chondrocytes in
areas of known MMP activity in growth cartilages and was in-
creased in OA. Catabolic cytokines known to be involved in OA
increased expression of TM and EPCR. Taken together, these
results suggest that APC may be a physiologically important
activator of MMPs in cartilage and regulating its activity could be
a novel target in the treatment of cartilage breakdown in arthritis.
A53
MECHANICAL INJURY POTENTIATES THE COMBINED
EFFECTS OF TNF-α AND IL-6/sIL-6R ON
PROTEOGLYCAN CATABOLISM IN BOVINE CARTILAGE
Y. Sui1, X.-Y. Song2, J.H. Lee2, M. DiMicco1, S.M. Blake1,
H.-H. Hung1, I. James2, M.W. Lark2, A.J. Grodzinsky1
1Massachusetts Institute of Technology, Cambridge, MA,
2Centocor R&D, Inc., Radnor, PA
Purpose: The elevated levels of injury-induced pro-inflammatory
cytokines in the joint may play pivotal roles in the pathogenesis
of osteoarthritis. The objective of this study was to examine the
combined effects of TNF-α and IL-6/sIL6R on proteoglycan (PG)
degradation in mechanically-injured cartilage.
Methods: Immature bovine cartilage disks (3 mm diam, 1 mm
thick) from femoropatellar grooves were treated with either injuri-
ous compression (50% strain, 100%/second strain rate), rhTNF-α
(25 ng/ml), rhIL-6 (50 ng/ml) plus sIL-6R (250ng/ml), or combi-
nations of these three conditions. Culture was terminated after
6 days of treatment. In separate experiments, half the cartilage
disks were pre-equilibrated for 6 days with an IL-6 blocking Fab
fragment (50 ug/ml, Centocor, J&J) while the remaining disks
were incubated in normal medium. Afterward, disks were treated
with injurious compression, rhTNF-α (25 ng/ml), or injury + TNF-
α. Disks that were pre-treated with the Fab fragment continued to
receive it until the end of the experiment. sGAG release (DMMB)
and biosynthesis (35S-PG) were measured, and Western blot-
ting to identify G1-NITEGE aggrecan fragments was performed
on pooled medium. Selected cartilage samples were fixed in
gluteraldehyde (with RHT) and stained with Toluidine Blue.
Results: 3-way ANOVA followed by post-hoc Tukey’s pairwise
comparisons showed that TNF-α formed interactions with both
IL-6/sIL-6R and injurious compression causing increased sGAG
release and decreased PG synthesis. While IL-6/sIL-6R signif-
icantly augmented TNF-α-induced PG degradation, the largest
amount of GAG loss was caused by the combination of injury +
TNF-α + IL-6/sIL-6R. Histology showed that GAG loss was not
uniform in the disk cross-section but progressed from the disk
periphery towards the center with time. The most rapid, severe
GAG loss was observed in disks treated with the combination
of injury + TNF-α + IL-6/sIL-6R. Western blotting demonstrated
that the most dramatic release of aggrecanase-generated aggre-
can fragments occurred in response to treatment with TNF-α +
IL-6/sIL-6R, both with and without injurious compression. In sep-
arate studies, TNF-α + mechanical injury caused greater GAG
loss than either treatment alone. Importantly, the IL-6 blocking
Fab fragment significantly reduced the combined catabolic effects
of TNF-α + mechanical injury on GAG loss, with no exogenous
IL-6 present.
Conclusions: The combined treatment with TNF-α and IL-6/sIL-
6R induced significantly more GAG loss than either cytokine
alone, and this catabolic response was associated with aggre-
canase activity. Additionally, the catabolic effect of TNF-α, and
the combined effect of TNF-α + IL-6/sIL-6R are both highly po-
tentiated by mechanical injury. The degradative effects of injury
+ TNF-α appear to be due, in part, to the action of endogenous
IL-6, as sGAG loss was partly abrogated by the IL-6 blocking
Fab fragment. This result is also consistent with the increased
loss of sGAG upon addition of exogenous IL-6 to the combi-
nation of TNF-α and mechanical injury. Histology suggests that
the kinetics of cartilage degradation does not merely depend
on the activity of proteolytic enzymes, but also relies strongly
on the transport of cartilage biomolecules, which may be al-
tered by overload injury. In conclusion, this study suggests that
pro-inflammatory cytokines can interact to potentiate cartilage
catabolism. Chondrocyte-mediated catabolism, as well as trans-
port of cytokines and proteases in the matrix, may both be altered
by joint injury, making the damaged tissue more susceptible to
further degradation by biochemical mediators.
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Purpose: Calcitonin has recently been proposed as an effective
drug for the treatment of osteoarthritis (OA). We investigated
whether treatment with salmon calcitonin influences the local
content of proteoglycans in human OA articular cartilage and
whether treatment with oral salmon calcitonin effects articular
cartilage erosion in an in vivo experimental model of OA.
Methods: For investigations of chondrocyte-mediated effects of
salmon calcitonin we used human OA cartilage obtained from
knee arthroplasty operations, which was dissected into 12-14
mg explants and cultured for 16 days in four replicates with
refreshment of medium every second day in the presence or
absence of salmon calcitonin [1 nM-1 mM]. MMP-13 ELISA was
used to quantify MMP-13 activity in the conditioned medium, and
sulphated glycosaminoglycan (sGAG) was measured in N2 pul-
verized explants extracts by the alcian blue binding assay. The
ovariectomized (OVX) rat was used as a non-traumatic model
of accelerated cartilage loss accompanying estrogen deficiency.
Fifty rats were randomly allocated into five intervention groups
and treated for nine weeks: 1) Sham, 2) OVX, 3) OVX + s.c.
implanted 17-β-ethynyl-estradiol pellet, 4) OVX + daily oral dose
calcitonin [2 mg/kg] + vehicle, 5-CNAC [50 mg/kg], and 5) OVX
+ daily oral dose of vehicle 5-CNAC [50 mg/kg]. Extracts of
entire articular joints was used for biochemical analysis. The
articulatio cubiti joint were isolated, snap-frozen, pulverized in N2
and resuspended with protease inhibitors, and fragments of C-
